ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Phase of Trial: Phase III
Latest Information Update: 05 Jun 2018
At a glance
- Drugs Sorafenib (Primary) ; Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms ASSURE
- 05 Jun 2018 Results of a retrospective subgroup analysis of this study, presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
- 18 Jul 2016 Status changed from active, no longer recruiting to completed.
- 10 Mar 2016 Primary endpoint has not been met. (Disease-free survival (DFS)), as per results published in the Lancet.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History